IP Library › Patent Application 11929856
Patent Application
App. No. 11/929,856

Pancreatic Cancer Genes

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/929,856
Abstract

The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.

Claims (14)

1 . An antibody preparation which specifically binds to a polypeptide encoded by SEQ ID NO: 2.

2 . The antibody preparation of claim 1 , wherein said antibody is a monoclonal antibody.

3 . The antibody preparation of claim 1 , wherein said antibody is a polyclonal antibody.

4 . The antibody preparation of claim 1 , wherein said antibody is labeled.

5 . The antibody preparation of claim 1 , wherein said antibody is a single chain antibody.

6 . The antibody preparation of claim 5 , wherein said antibody is mono-specific.

7 . The antibody preparation of claim 5 , wherein said antibody is bi-specific.

8 . The antibody preparation of claim 5 , wherein said antibody is bivalent.

9 . The antibody preparation of claim 5 , wherein said antibody is tetravalent.

10 . A composition comprising an amount of an antibody which specifically binds the polypeptide encoded by SEQ ID NO: 2; and a pharmaceutically acceptable carrier, said amount effective to reduce the growth rate of contacted cancer cells by at least 50% as compared to a control.

11 . A method for treating dysplasia in a patient having said dysplasia, said method comprising administering to said patient a composition comprising an amount of an antibody which specifically binds the polypeptide encoded by SEQ ID NO: 2; and a pharmaceutically acceptable carrier, said amount effective to reduce the growth rate of contacted dysplastic pancreatic cells by at least 50% as compared to a control.

12 . The method of claim 11 , wherein said dysplasia is pancreatic dysplasia.

13 . A method for treating cancer in a patient having said cancer, said method comprising administering to said patient a composition comprising an amount of an antibody which specifically binds the polypeptide encoded by SEQ ID NO: 2; and a pharmaceutically acceptable carrier, said amount effective to reduce the growth rate of contacted pancreatic cancer cells by at least 50% as compared to a control.

14 . The method of claim 13 , wherein said cancer is pancreatic cancer.